BMS creates strategic leadership committee

Share this article:
Lamberto Andreotti
Lamberto Andreotti

Bristol-Myers Squibb (BMS) has created an executive committee of four, which will serve as the company's “senior strategy and decision-making body,” according to a BMS statement.

Lamberto Andreotti was promoted from EVP to president, and retained his role as COO. He was also tapped as a member of the executive committee, along with Elliott Sigal, EVP, chief scientific officer and president of R&D, Jean-Marc Huet, EVP and chief financial officer, and Jim Cornelius, chairman and CEO.

Tracy Furey, a BMS spokesperson, told Bloomberg that the committee will guide development of the company's experimental drugs, pursue small biotechnology companies and strike profit-sharing deals for new products.

In addition to establishing the committee, BMS announced several other promotions and appointments:

  • Anthony Hooper to president, Americas
  • Beatrice Cazala to president, global commercialization, and president, Europe
  • John Celentano to president, emerging markets and Asia-Pacific
  • Carlo De Notaristefani to president, technical operations and global support functions
  • Giovanni Caforio to SVP, global and US oncology

In a separate announcement, BMS said it will collaborate with two Japanese companies—Nissan Chemical Industries and Teijin Pharma Limited—to develop and commercialize NTC-801, an experimental treatment for abnormal heart rhythm, or atrial fibrillation.

Under the terms of the deal, which includes an up-front payment of $40 million and potential milestone payments in the future, BMS will obtain exclusive licensing rights to the drug worldwide, except in Japan.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...